Comparative Study of Novel Prognostic Scores in Patients With Liver Cirrhosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-01

Study Completion Date

2027-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. To determine the prognostic performance of novel scores in predicting complications and in-hospital mortality in patients with liver cirrhosis.
2. To compare the accuracy of these scores in identifying high risk patients relative to the standard scores.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Short Term Outcomes in Hospitalized Patients With Liver Cirrhosis

NCT05848414

Liver Cirrhosis

COMPLETED

Assessment of Severity of Liver Disease Before Surgery

NCT05503836

Cirrhosis, Liver

UNKNOWN

Prognosis of Patients With Acute-on-chronic Liver Failure

NCT05393453

Acute-On-Chronic Liver Failure

UNKNOWN

Haemostatic Imbalance in Patients With Chronic Liver Disease

NCT03589430

Haemostasis Imbalance in Chronic Liver Disease

UNKNOWN

Prognosis Scoring System for Acute-on-Chronic Liver Failure

NCT01961440

Liver Failure

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Liver cirrhosis represents the end stage of chronic liver diseases and remains a major global health burden, accounting for over 1 million deaths annually.
* It is characterized by progressive fibrosis, nodular regeneration, and architectural distortion of the liver parenchyma, ultimately leading to liver dysfunction and portal hypertension
* Once acute decompensation occurs the prognosis significantly worsens, with a sharp increase in short-term mortality
* Accurate outcome prediction in cirrhotic patients is essential for guiding early interventions, allocating healthcare resources, and prioritizing liver transplant listing.
* Traditional prognostic scores, such as the Child-Turcotte Pugh (CTP) and Model for End-Stage Liver Disease (MELD), have important limitations.
* CTP includes subjective variables, while MELD may not fully reflect clinical deterioration in early decompensation
* MELD is widely used to predict the short-term mortality in patients with cirrhosis, but potential limitations of this score have been reported.
* An integrated MELD model (iMELD) including serum sodium and age improves the prediction of early mortality in patients with cirrhosis The Chronic Liver Failure Consortium Acute Decompensation (CLIF-C AD) score, introduced by European Association for the Study of the Liver (EASL), was specifically designed for hospitalized patients with acute decompensation (without Faculty of Medicine Institutional Review Board (IRB) Assiut Medical School Research Proposal Form 3 ACLF). It incorporates age, white blood cell count, and organ function to better stratify risk
* Recently, newer prognostic models such as the ADRECIA score have been developed, incorporating variables such as inflammatory markers and kidney function. These models aim to further refine risk stratification in cirrhosis, especially in early decompensation, before organ failure sets in
* Although these novel scores show promise in identifying patients at high risk for deterioration or death, direct comparisons in real-world clinical settings are lacking.
* Understanding their relative performance could help optimize the management of hospitalized patients with AD cirrhosis, thereby facilitating early clinical decision-making, optimizing patient outcomes, and potentially improving resource allocation in hepatology care settings.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cirrhosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Usage of new scores

usage of new scores for prediction of morbidity and mortality in patients with liver cirrhosis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Age ≥ 18 years

* Diagnosis of liver cirrhosis (clinical, radiological using ultrasound or fibroscan)
* Hospital admission for acute decompensation (ascites, hepatic encephalopathy, variceal bleeding, SBP)

Exclusion C• Previous liver transplantation

* Pregnancy
* Refusal to participate in the study riteria:

Eligible Sex

ALL

Accepts Healthy Volunteers

No